We observed an increasing trend of MRD +/DFS event rates associated with increasing CRF scores, with no events in the “CRF 0” group, escalating to 26.9% for the “CRF 1” group and 50.0% for the “CRF 2” group (χ 2 test, P < 0.001) (Fig. 3 C).
← all excerpts
Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.
1
—
—